Millendo’s Julia Owens on leadership in rare diseases
Rare disease specialists Millendo Therapeutics are hoping their drug livoletide will become the first treatment for Prader-Willi syndrome. Founder and CEO Julia Owens spoke to Paul Tunnah at JP Morgan about the challenges in orphan therapies and the company’s rapid growth.
About the interviewee
Dr Julia C. Owens co-founded Millendo Therapeutics in 2012 and has served as President and Chief Executive Officer since its inception. Dr Owens has an extensive track record of building successful biopharmaceutical companies, with particular expertise in business development, strategic partnerships and mergers and acquisitions. Prior to co-founding Millendo, she served as senior vice president, corporate development and strategy at Lycera.